The POMT2 gene gives your cells instructions for a protein that starts adding sugar tags to certain proteins, especially one needed for healthy muscle, brain, and eye development. This gene helps your body build stable links between cells and the tissue around them. If both copies of the POMT2 gene do not work properly, a person can have an inherited condition in the muscular dystrophy group, with low muscle tone, weakness, delayed development, and sometimes brain or eye changes. POMT2 is mainly known in medical genetics rather than popular culture.
What is a gene?
Genes are stretches of DNA that carry instructions your cells use to make molecules or regulate activities in the body. Some genes provide the code for proteins, which do much of the cell’s work. Others mainly control when a process takes place, where it happens, and how active it is. Together, genes affect how your body develops and works, and they can also influence how you respond to food, stress, and medications. For a closer look at this topic, you can find more in the LearnHub.
Overview
POMT2Gene function
What if the gene works
The POMT2 gene helps cells add a sugar tag to certain proteins. This step supports how muscle, brain, and eye tissues develop and helps cells stay connected to their surrounding support structure.
Risk
What if the gene does not work
Variants in the POMT2 gene can disrupt alpha-dystroglycan, causing a spectrum of dystroglycanopathy. Depending on the variant, this may range from severe congenital muscle weakness with brain and eye changes to milder later-onset muscle disease.
Treatment
What does that mean for your treatment
For people with a pathogenic or loss-of-function variant in the POMT2 gene, no POMT2-specific treatment or management approach is currently established. POMT2-related disease is part of a broader treatment research area in muscular dystrophy, but these approaches remain investigational.
Conditions associated with POMT2
Gene function
What if the gene works
Inside your cells, the POMT2 gene helps attach a small sugar called mannose to a select group of proteins. This early finishing step helps those proteins work properly and reach the right place. Understanding how the POMT2 gene works helps explain how cells prepare key surface proteins for daily use.
The POMT2 gene helps start a process called O-mannosylation, which means adding mannose to certain proteins. This sugar tag is an early step that helps those proteins mature normally.
Its protein works together with the POMT1 protein inside a cell area called the endoplasmic reticulum (the protein processing area). Together, they carry out the first step of mannose attachment.
This sugar marking is especially important for alpha-dystroglycan, a protein that helps cells grip the surrounding support material. That connection supports steady structure and signaling in tissues such as muscle and brain.
What is a variant?
A genetic variant is a minor change in a gene’s DNA sequence. These changes are common and help shape normal human diversity, including differences in appearance, metabolism, and the way the body reacts to environmental factors. Many variants do not have any noticeable effect and are part of natural genetic variation. At times, though, a variant can change how a gene works more significantly and may contribute to, or directly cause, a genetic condition.
Genetic variants
What if the gene does not work
Variants in the POMT2 gene often make the protein unstable, shortened, or less able to work with its partner, so cells add too few sugar tags to a key surface protein that helps tissues stay connected. Milder variants may leave some activity, while more severe variants can nearly shut this process down. This range in functional effect can influence how early POMT2-related dystroglycanopathy appears and how wide-ranging it is.
How variants are linked to conditions
Pathogenic variants in the POMT2 gene cause a group of inherited conditions called dystroglycanopathies, including Walker-Warburg syndrome, muscle-eye-brain disease, and some forms of limb-girdle muscular dystrophy. In people with POMT2 gene variants linked to muscular dystrophy, features can range from severe problems present at birth to milder muscle weakness that appears later, and some also have eye or brain involvement.
A variant is not necessarily a diagnosis
Genetic variants are a routine part of human biology and are widespread in the general population. Most do not have a direct effect on health and instead reflect normal human diversity. For many genes, carrying a variant associated with a condition indicates a possible link rather than a definite diagnosis, especially when several genes and environmental factors both play a role. In some situations, though, a single well-characterized variant in a particular gene is enough to confirm a diagnosis.
Are there things that can increase or change my risk?
For POMT2, risk is mainly shaped by inheritance, not lifestyle. A child is affected when both copies of the gene have a harmful change, so risk is higher when both parents carry one or when the change runs in the family; it can also be higher in families where the parents are related by blood. There is not enough evidence to say that diet, exercise, or other everyday habits change this genetic risk.
Inheritance of POMT2 variants
POMT2-related conditions follow an autosomal recessive inheritance pattern. In practical terms, how variants of the POMT2 gene are inherited usually means a child must receive one changed copy from each parent to have the condition. Parents who each carry one POMT2 variant are often unaffected themselves, and with each pregnancy there is a 25% chance the child inherits both variants, a 50% chance the child is a carrier, and a 25% chance the child inherits neither variant. This pattern applies equally to sons and daughters.
What does my POMT2 result mean for my family?
For families with a disease-causing POMT2 result, this condition usually runs in a recessive pattern, which means close relatives may also be carriers even if they have no symptoms. Brothers and sisters can sometimes be affected or carry the same gene change, and parents are often carriers. Other relatives on both sides of the family may also carry it.
Genetic information
Genetic testing
How you find out about variants
POMT2 genetic testing looks for changes in the POMT2 gene using a blood sample, saliva, or sometimes a cheek swab. A lab reads the gene's DNA to check for variants that may help explain a person's symptoms or confirm a suspected inherited condition. Results usually classify findings as benign, uncertain, or pathogenic.
When should I consider getting a genetic test?
Genetic testing for the POMT2 gene may be worth discussing if a baby or child has unexplained muscle weakness, delays in sitting or walking, learning difficulties, or brain or eye changes, especially when similar problems run in the family. Testing can help confirm an inherited muscle condition.
A genetic result is only one part of your health story
Genetic test findings can provide meaningful insight, but how much they explain depends on the condition and the kind of variant involved. Many factors, including lifestyle, environment, age, and medical history, also influence how the body functions over time. For some conditions, especially those shaped by many genes, genetic information offers context rather than certainty and is best understood together with other parts of care. In other situations, a genetic result may give a clear answer. In areas such as medication response, genetic results can help put individual experiences into perspective.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how people respond to medicines. Two people can take the same treatment, yet one may get the expected benefit while the other may notice less effect or more side effects. One reason is that inherited differences can change how the body breaks down, moves, or responds to a drug. These differences are common and can influence how well a medication works or how sensitive someone is to it.
What is Pharmacogenetics?
Pharmacogenetics examines how genetic differences affect the way people respond to medicines. It studies links between genes and drugs to help explain why the same treatment may work differently from one person to another. For many medications, genes influence both how strongly a drug works and how the body handles it. This information can support treatment decisions that are more informed and more individualized. You can read more about this topic in the LearnHub.
Drugs influenced by the POMT2 gene
When should I seek medical advice?
There is not yet a broadly confirmed role for this gene in guiding how medicines are chosen or how well they work. Questions about medications, side effects, or changes in your health are best discussed with your doctor or pharmacist.
History
POMT2 entered medical genetics in the early 2000s, when researchers studying families with severe inherited muscle and brain conditions began linking the same gene to Walker-Warburg syndrome. Soon after, variants in the POMT2 gene were also identified in people with milder but related forms of congenital muscular dystrophy. From these first observations, research expanded steadily. Doctors and scientists then recognized that POMT2 belonged to a broader group of genes involved in dystroglycanopathies, a family of conditions affecting muscle, brain, and sometimes eye development. Over time, descriptions became more precise as genetic testing made it easier to connect different symptom patterns to the same gene. This history helped turn what once looked like several separate conditions into a more unified genetic picture.